@Article{Janecki2014,
journal="Medycyna Paliatywna/Palliative Medicine",
issn="2081-0016",
volume="6",
number="4",
year="2014",
title="Management of cancer pain with neuropathic component using transdermal buprenorphine – three clinical cases report",
abstract="Pain is one of the most dominant symptoms in patients with advanced or disseminated cancer, having negative influence on quality of life. Although opioids are mainstream approach in controlling moderate to severe pain, lots of patients are still suffering. One of the responsible reason may be neuropathic component of the cancer pain. The launch of transdermal buprenorphine in 2001 restored interest in the use of the drug to treat moderate to severe cancer pain and some evidence from human clinical trials support it effectiveness in managing neuropathic pain. In this report three clinical cases of patients suffering from chronic cancer pain with neuropathic component treated with transdermal buprenorphine were presented. In all cases buprenorphine tended to be very effective, with favorable safety profile, especially in the group of elderly patients.",
author="Janecki, Marcin
and Pakosz, Artur",
pages="220--224",
url="https://www.termedia.pl/Management-of-cancer-pain-with-neuropathic-component-using-transdermal-buprenorphine-three-clinical-cases-report,59,24902,1,1.html"
}